from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in

Chicago, IL. Join Oleg Gluz of Evang. Krakenhaus “Bethesda” Klinik, Jana de

Boniface of the Karolinska Institutet, Peter Schmid of Queen Mary University of

London and Erika Hamilton of the Sarah Cannon Research Institute as they

discuss key trials and what this means for clinical practice. They explore pooled

analysis from the ADAPT and PlanB trials, results from the SENOMAC trial of

axillary lymph node dissection omission, menopausal status data from the lidERA

trial, final analysis from KEYNOTE-522 and subgroup analyses from

HER2CLIMB-05.